Detail akcie OKYO Pharma Rg online

Business Summary: OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
Financial Summary: BRIEF: For the six months ended 30 September 2025, OKYO Pharma Ltd revenues was not reported. Net loss decreased 3% to L2.6M. Lower net loss reflects Pharmaceuticals segment loss decrease of 25% to L2.5M. Basic Earnings per Share excluding Extraordinary Items increased from -L0.08 to -L0.07.